SCHEMBL5550778

SCHEMBL5550778

NC(=O)c1cc2c(-c3ccc(C(=O)O)cc3)cncc2s1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 11/20 0.78
GSK3A P49840 11/20 0.78
GSK3B P49841 10/20 0.78
CDK2 P24941 10/20 0.78
DYRK1A Q13627 10/20 0.78
CDK5 Q00535 9/20 0.78
KDR P35968 9/20 0.78
CHEK2 O96017 9/20 0.78
MAPK9 P45984 9/20 0.78
CSNK1D P48730 9/20 0.78
CDK1 P06493 9/20 0.78
LIMK1 P53667 8/20 0.78
DAPK3 O43293 8/20 0.78
AURKB Q96GD4 8/20 0.78
PLK4 O00444 8/20 0.78
AURKA O14965 8/20 0.78
RPS6KA3 P51812 7/20 0.78
CSNK2A1 P68400 7/20 0.78
PRKACA P17612 7/20 0.78
SGK2 Q9HBY8 7/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056743 0.88 GSK3A (1.00) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL5555786 0.86 PIM1 (0.78) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL7050653 0.85 GSK3A (1.00) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL7055360 0.85 PIM1 (0.76) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL7055380 0.85 PIM1 (1.00) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL19769161 0.83 PIM1 (0.79) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL5550833 0.82 ICAM1 (0.70) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL7057944 0.82 PIM1 (0.80) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL19780465 0.82 PIM1 (0.71) PIM1GSK3AGSK3BCDK2DYRK1A
SCHEMBL19769135 0.82 PIM1 (0.71) PIM1GSK3AGSK3BCDK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 PIM1 252/4885GSK3A 453/4885GSK3B 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.